Categories: News

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results

Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference

BURNABY, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced it will report its 2020 financial and operating results after the close of U.S. financial markets on Monday, March 1, 2021:

  • Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on Monday, March 1, 2021 to discuss the year-end results and to provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 6061326.

In addition, Xenon will participate in a fireside discussion at the following upcoming virtual investor conference, which will be webcast live on the Investors section of the Xenon website:

  • SVB Leerink 10th Annual Global Healthcare Conference at 10:00 am Eastern Time on Wednesday, February 24, 2021.

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

Read moreFossil launches its first smartwatch on the Qualcomm Snapdragon Wear 3100 platform

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

Staff

Share
Published by
Staff
5 years ago

Recent Posts

SetPoint Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people…

1 hour ago

SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion

NEW YORK--(BUSINESS WIRE)--SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused…

1 hour ago

Apyron Pioneering Next Generation Pain Management Solutions

Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company…

1 hour ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has…

1 hour ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes…

1 hour ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s mNEXSPIKE (COVID-19 Vaccine, mRNA)

mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine,…

1 hour ago